The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

By Arlene H. Sharpe, E. Wherry, Rafi Ahmed, G. Freeman. Nature Immunology, 2007

1,601 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d24a07c8cb7978ff2a40e8b5f5b881e81ad052df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways (2008, background): “It has also been suggested that exhausted CD8(1) T cells move from partial to full exhaustion as CD4(1) T-cell help decreases and antigen load and PD-1 increase (112).”
IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade (2017, neutral): “Kenilworth, New Jersey, USA: Merck Sharp & Dohme Corp.; 2017.”
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (2015, background): “While the latter occurs focally at sites of IFNg-mediated immunologic attack, oncogene-driven PD-L1 expression is constitutive and diffuse (13).”
Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “Although they mostly help tumor rejection, Th1 cells might contribute to tumor escape via secretion of IFN-g that triggers expression of PDL-1 in tissues, thus providing an off signal to effector CD8+ T cells (Sharpe et al., 2007).”
The PD-1 Pathway in Tolerance and Autoimmunity (2010, background): “This pathway exerts critical inhibitory functions in the setting of persistent antigenic stimulation such as during encounter of self-antigens, chronic viral infections, and tumors (6, 9).”
Redefining chronic viral infection. (2009, positive): “These results have been extended to humans where the PD-1:PD-L pathway regulates HIV-, HBV-, and HCVspecific T cells in vitro (Sharpe et al., 2007).”
Antigen independent differentiation and maintenance of effector-like resident memory T cells in tissues (2012, background): “PD-1 is upregulated upon TCR stimulation and is often maintained on CD8 T cells during chronic infection (46).”
PD-1/PD-L1 pathway: current researches in cancer. (2020, background): “PD-L1 is usually expressed by macrophages, some activated T cells and B cells, DCs and some epithelial cells, particularly under inflammatory conditions [18].”
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. (2007, background): “because it has been found to mediate clonal exhaustion and T cell anergy in HIV and other chronic viral infections (34) as well as tolerance to self antigens and immune suppression in cancer (35).”
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. (2013, background): “PD-1 expression is indicative of chronic antigen stimulation and contributes to T cell dysfunction (exhaustion)(19).”
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection (2010, background): “However, blockade of PD-1 pathway does not completely restore T-cell function (4, 5, 7), indicating the involvement of other negative regulatory pathways in CD8 T-cell exhaustion.”
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. (2019, background): “Although early studies first described T cell exhaustion during chronic LCMV infection (4, 5), it is clear that T cell exhaustion occurs in many other chronic viral infections, including HIV (12–15), hepatitis C virus (HCV) (16, 17), hepatitis B virus (HBV) (18), and other persisting infections (19)”
Coregulation of CD8+ T cell exhaustion during chronic viral infection by multiple inhibitory receptors (2008, background): “PD-1, an inhibitory receptor in the CD28 'superfamily”
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells (2010, background): “It has been suggested that PD-1 is increased during viral infection to inhibit chronically activated T cells from causing immunopathology or becoming autoreactiv”
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors (2013, background): “(5) Blocking antibodies against PD-1 or PD-L1 have demonstrated substantial clinical activity in patients with metastatic melanoma, renal cell carcinoma, non-small cell lung cancer, and other tumors (6, 7).”